A 2026 clinical review examines the evidence linking testosterone therapy with tendon injury. Learn the proposed mechanisms and practical military health advice.
The shoulder pop happened during a routine overhead press. A veteran who felt stronger than he had in years suddenly faced a severe joint issue. The tension between feeling physically revitalized and experiencing sudden joint failure is a reality many men navigate. Are testosterone treatments putting your connective tissues at risk?
Reviewing my blood work for the first time felt overwhelming. There was so much confusing information out there about testosterone and hormones. I wanted clear facts and evidence based guidance, not a sales pitch. That experience showed me how critical it is to separate established science from marketing hype.
The conversation around hormone therapy often ignores how structural tissues adapt to changing physiological loads. Connective tissues require time to build density and strength. We need to look closely at the clinical data surrounding testosterone and hormones to understand the full picture. Examining the science helps us make informed decisions about physical capability.
A 2026 review published in Cureus examines the clinical evidence connecting testosterone therapy with tendon injury. The research investigates the biological mechanisms and the implications for sports medicine. This review highlights an association between androgen exposure and several connective tissue issues. It is important to remember that this evidence demonstrates an association rather than proof of direct causation.
The current literature focuses on whether testosterone exposure influences tendon structure and repair. These tissues undergo constant mechanical stress during active service and regular fitness training. Understanding how hormones affect this stress is vital for long term performance. The available findings justify clinical attention to tendon symptoms and training progression.
The strongest relevant evidence comes from a retrospective cohort study of active-duty service members. This study was published in Military Medicine in August 2026. The researchers analyzed active-duty personnel from January 2011 through June 2024. They utilized military medical records, pharmacy records, demographic data, and service records.
The male cohort included 3,008,346 service members. The study tables identified 13,209 men with current or prior androgen therapy. Among these androgen users, 5,275 men had a recorded connective tissue injury during observation. This figure represents 39.9 percent of the androgen exposed group.
The researchers adjusted their survival models for age and race. They also adjusted for Hispanic ethnicity, military rank, and body mass index. This comprehensive approach allowed researchers to identify broad trends across a massive population.
Androgen exposure was associated with a 43 percent higher adjusted hazard of any connective tissue injury. The overall adjusted hazard ratio for male service members was 1.43. The study also reported an adjusted hazard ratio of 1.85 for any tendon rupture. Upper-body tendon ruptures showed a higher adjusted hazard ratio of 2.24.
Lower-body tendon ruptures showed an adjusted hazard ratio of 1.53. The data also indicated an adjusted hazard ratio of 1.99 for rotator-cuff rupture. The same analysis associated androgen therapy with trigger finger, carpal tunnel syndrome, and sprains. The adjusted hazard ratios for these conditions were 2.03, 2.44, and 1.50 respectively.
The article narrative also notes authors rounded estimates of approximately 2.1 for tendon rupture and 2.5 for trigger finger. The narrative rounded estimates also included 3.0 for carpal tunnel syndrome and 1.6 for sprains. These figures reinforce the association across multiple structural sites in the body.
The military study analyzed the time to event for these connective tissue injuries. The authors reported an average time to tendon rupture of 68.8 months among men with up to 360 days of androgen therapy. This was compared to an average time to tendon rupture of 72.1 months among men without androgen therapy. This represents a difference of 3.3 months between the two groups.
This time difference does not prove that testosterone directly caused an earlier rupture. It does support the clinical concern that injury risk may be particularly relevant after therapy begins. An acute physiological change could occur shortly after a patient initiates treatment. Monitoring structural health during this window is a practical consideration for military health professionals.
The study authors discuss several possible biological mechanisms that could explain this association. One proposed mechanism involves rapid changes in tenocyte proliferation and insulin-like growth factor 1 production. These biological shifts could alter the delicate balance between tissue growth and mechanical adaptation. If tissue remodeling cannot keep pace with new loads, the structure may weaken over time.
Another mechanism suggests testosterone related changes in tendon stiffness could increase mechanical stress. This stress occurs when muscle strength rises faster than the tendon can adapt. A service member might return to demanding lifting or rucking before the tissue is ready. Muscle bellies often respond rapidly to hormonal changes while tendons take significantly longer to adapt.
Another proposed mechanism involves changes in tendon matrix metalloproteinases. These are enzymes involved in extracellular matrix turnover and structural remodeling. The authors also discuss possible effects of tissue volume changes within confined spaces. Hypervolemia within the carpal tunnel and flexor tendon sheath could potentially help explain specific injuries.
A separate systematic review and meta-analysis published in the European Journal of Endocrinology in 2026 examined fracture outcomes. This analysis looked at men with hypogonadism receiving testosterone therapy. The reported finding was that therapy was associated with increased predominantly non-major fractures. However, major osteoporotic fracture risk was not increased.
These major osteoporotic risks included hip and vertebral fractures. This fracture evidence does not establish a specific tendon effect. It does reinforce the broader need to evaluate musculoskeletal outcomes beyond just serum testosterone. Tendons and bones are distinct tissues that respond differently to hormonal changes and mechanical loads.
The active-duty study was retrospective and observational in nature. This structure means it cannot prove that androgen therapy explicitly caused the tendon ruptures or other injuries. Confounding variables remain a significant factor in interpreting the results. A population level association cannot determine whether a particular elbow or hand problem was caused by treatment.
The androgen exposed group had an average age of 40.2 years versus 27.7 years for the unexposed group. The exposed group also had a higher average body mass index of 30.3 compared to 26.8. These age and size differences highlight why observational data must be interpreted carefully. Older age and higher body mass are independent risk factors for many structural injuries.
The study lacked detailed data on training volume and prior injuries. Biomechanics and occupational exposures were also not captured in the military records. The exposure category included pharmaceutical products intended to increase or replace testosterone. The data source identified pharmaceutical androgen exposure but did not capture illicit anabolic steroid use.
The study also could not capture actual hormone concentrations or medication adherence. The evidence does not show that therapy improves tendon healing or reliably accelerates tendon repair. Supraphysiologic anabolic steroid exposure may involve different doses and behaviors than physician managed replacement therapy. Understanding these nuances prevents patients from jumping to inaccurate conclusions.
A critical factor in injury prevention is managing how physical stress is applied to the body. Strength gains and changes in body mass often occur before connective tissue has fully adapted. The safest practical approach is to avoid abrupt increases in training load when adjusting therapy. Graded progression, adequate recovery, and structured rehabilitation are essential.
Do not use early strength gains as evidence that your tendons are ready for maximal loading. Pushing through heavy tactical training too soon can overwhelm joint structures. A service member should implement a progressive loading protocol that allows tissues time to remodel. Adapting your training volume slowly helps mitigate the mechanical stress placed on rigid tendons.
A service member or veteran considering treatment should discuss more than just hormone numbers. The conversation should include any prior tendon injuries and current pain or joint stiffness. You should also outline your occupational tasks involving repetitive gripping, sprinting, jumping, or heavy loads. Clinicians treating military personnel may want to document the exact formulation, dose, and adherence.
A new tendon symptom after changing therapy deserves timely and serious evaluation. Symptoms like sudden weakness, a popping sensation, or visible deformity require immediate attention. Loss of strength or rapidly worsening swelling should also prompt timely evaluation. Patients should never independently stop, increase, or change prescribed testosterone without medical supervision. Discussing these elements with your doctor helps build a more resilient approach to veteran life.
Treatment decisions must account for the specific reason testosterone therapy was prescribed alongside laboratory monitoring and symptoms. The available military evidence shows an association that warrants careful attention to physical training habits. Building long term capability requires understanding how biological treatments interact with physical stress and tissue recovery. If your muscle output outpaces your connective tissue capacity, your injury risk will inevitably climb. Evaluate your current training load today and reduce any rapidly increasing volume to protect your joints.
Follow BattleVet for practical guidance on military and veteran health, strength, recovery, testosterone, sleep and healthy aging. Stay connected for new articles, research backed insights and clear information to help you stay capable for the years ahead.
New cardiology data links lower fitness to higher coronary calcium and increased dementia risk. Learn why aerobic conditioning protects long-term brain health.
Meaningful work and a clear mission are critical for veterans navigating the transition to civilian employment. Learn how to balance purpose and salary.
Improve military readiness by prioritizing active mobility over passive flexibility. Learn to build usable range of motion and control for field tasks.
Build better habits around strength, recovery, sleep, hormones and healthy aging with practical guidance for active military personnel and veterans.
Explore BattleVet